Back to Bevacizumab

Bevacizumab

Showing 15 study arms with grade ≥3 adverse event data (treatment-related and RT-related). Click a column header to sort.

Note on patient counts: some articles reported only percentages rather than absolute numbers. Where this occurred, the number of patients — including those with grade ≥3 adverse events — was derived by applying the reported percentage to the total arm size, which may produce a non-integer value. These figures have been rounded to the nearest integer for display.

1st Author⇅	Year⇅	Study Type⇅	Title⇅	DOI⇅	clinical trial number⇅	number of patients⇅	median/mean age⇅	tumor type⇅	treatment setting⇅	drug group⇅	drug name⇅	if other, please specify⇅	number of SBRT courses⇅	intracranial / extracranial⇅	treated site⇅	If other treated site, please specify⇅	median/mean total RT dose [Gy]⇅	minimum total RT dose [Gy]⇅	maximum total RT dose [Gy]⇅	median/mean number of fractions⇅	minimum number of fractions⇅	maximum number of fractions⇅	median/mean dose per fraction [Gy]⇅	minimum dose per fraction [Gy]⇅	maximum dose per fraction [Gy]⇅	toxicity type⇅	patients with acute G>=3 toxicity⇅	patients with late G>=3 toxicity⇅	patients with G>=3 toxicity, timing unspecified⇅	G>=3 AEs⇅	patients with G>=3 AEs⇅	details on G>=3 toxicity⇅	details on G>=3 toxicity in RT field⇅
Looman et al.	2026	Prospective	Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer Therapy	10.1001/jamanetworkopen.2025.53809	—	3	62	Breast cancer, Lung cancer, Prostate cancer, Colorectal cancer, Head and neck cancer, Esophagus cancer, Melanoma, Kidney cancer, Bladder cancer, Sarcoma, other	oligometastatic, metastatic	VEGF mAb	Bevacizumab	—	Missing	extra-cranial	lung	—	—	—	—	Missing	1	10	—	—	—	RT-related	—	—	0	—	—	—	—
Looman et al.	2026	Prospective	Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer Therapy	10.1001/jamanetworkopen.2025.53809	—	6	62	Breast cancer, Lung cancer, Prostate cancer, Colorectal cancer, Head and neck cancer, Esophagus cancer, Melanoma, Kidney cancer, Bladder cancer, Sarcoma, other	oligometastatic, metastatic	VEGF mAb	Bevacizumab	—	Missing	extra-cranial	other	Abdomen	—	—	—	Missing	1	10	—	—	—	RT-related	—	—	0	—	—	—	—
Novak Filho et al.	2025	Retrospective	Radiosurgery for recurrent high-grade gliomas: a critical analysis based on a retrospective single-center series	10.1007/s10143-025-03907-1	—	23	51	brain	N/A	VEGF mAb	Bevacizumab	—	43	intra-cranial	brain	—	Missing	12	24	1	1	1	Missing	12	24	Radiation necrosis	—	—	0	—	—	—	—
Zheng et al.	2025	Prospective	Efficacy and safety of online adaptive magnetic resonance-guided fractionated stereotactic radiotherapy for brain metastases in non-small cell lung cancer (GASTO-1075): a single-arm, phase 2 trial.	10.1016/j.eclinm.2025.103189	NCT04946019	27	58	Lung cancer	metastatic	VEGF mAb	Bevacizumab	—	Missing	intra-cranial	brain	—	30	30	30	5	5	5	6	6	6	Treatment-rel.	—	—	0	—	—	—	—
Zhou et al.	2025	Prospective	Efficacy and safety of combining bevacizumab and fractionated stereotactic radiotherapy for extensive brain metastases in patients with non-small cell lung cancer: a prospective phase II study (GASTO-1053)	10.1002/cac2.70078	—	100	59	Lung cancer	oligometastatic, metastatic	VEGF mAb	Bevacizumab	—	Missing	intra-cranial	brain	—	Missing	30	40	Missing	5	10	Missing	4	6	Treatment-rel.	—	—	0	—	—	—	—
Wang et al.	2024	Retrospective	Outcomes of 2-SSRS plus bevacizumab therapy strategy for brainstem metastases (BSM) over 2 cm(3): a multi-center study	10.1007/s10143-024-02369-1	—	53	61	Breast cancer, Lung cancer, other	metastatic	VEGF mAb	Bevacizumab	—	63	intra-cranial	brain	—	23.5	Missing	Missing	2	2	2	Missing	10	13	Treatment-rel.	0	—	—	—	—	—	—
Zhang et al.	2024	Retrospective	Bevacizumab reduces cerebral radiation necrosis due to stereotactic radiotherapy in non-small cell lung cancer patients with brain metastases: an inverse probability of treatment weighting analysis.	10.3389/fimmu.2024.1399613	—	28	65.5	Lung cancer	oligometastatic, metastatic	VEGF mAb	Bevacizumab	—	Missing	intra-cranial	brain	—	Missing	18	30	Missing	1	5	Missing	5	24	Treatment-rel.	3	0	—	acute G3: 3 AEs	acute G3: 3 pts	acute G3: Leukopenia, neutropenia	—
Wang et al.	2023	Retrospective	Efficacy and safety of a "sandwich therapy" based on staged stereotactic radiosurgery and bevacizumab for large brainstem metastases	10.1016/j.clineuro.2023.107911	—	42	66.5	Breast cancer, Lung cancer, other	oligometastatic, metastatic	VEGF mAb	Bevacizumab	—	Missing	intra-cranial	brain	—	25	Missing	Missing	2	2	2	Missing	11	15	RT-related	—	2	—	acute G2-3: 8 AEs, late G3: 1 AE, late G5: 1 AE	acute G2-3: 6 pts, late G3: 1 pt, late G5: 1 pt	acute G2-3: nausea, headache, ataxia deterioration, late G3: Cerebral radiation necrosis, late G5: Cerebral radiation necrosis	—
Chen et al.	2021	Retrospective	Peri-radiosurgical administration of bevacizumab improves radiographic response to single and fractionated stereotactic radiosurgery for large brain metastasis	10.1007/s11060-021-03782-y	—	49	Missing	Breast cancer, Lung cancer, other	oligometastatic, metastatic	VEGF mAb	Bevacizumab	—	Missing	intra-cranial	brain	—	51.3	28	60	3	1	5	27	20	35	Treatment-rel.	—	—	4	any G3: 4 AEs	any G3: 4 pts	any G3: hypertension	/
Guan et al.	2020	Prospective	Hypofractionated Radiosurgery Plus Bevacizumab for Locally Recurrent Brain Metastasis with Previously High-Dose Irradiation	10.1016/j.wneu.2019.08.233	Missing	24	58	Breast cancer, Lung cancer, other	oligometastatic, metastatic	VEGF mAb	Bevacizumab	—	Missing	intra-cranial	brain	—	Missing	9.5	29	Missing	2	5	Missing	Missing	Missing	Treatment-rel.	1	—	—	acute G3: 2 AEs	acute G3: 1 pt	acute G3: fatigue and headache	acute G3: fatigue and headache
Clarke et al.	2017	Prospective	Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma	10.1016/j.ijrobp.2017.06.2466	NCT01392209	12	63	brain	any	VEGF mAb	Bevacizumab	—	12	intra-cranial	brain	—	30	27	33	3	3	3	10	9	11	RT-related	—	—	1	any G3: 1 AE	any G3: 1 pt	any G3: fatigue and cognitive deterioration	any G3: fatigue and cognitive deterioration
Guinde et al.	2017	Retrospective	Bevacizumab Plus Radiosurgery for Nonsquamous Non-Small Cell Lung Cancer Patients with Brain Metastases: Safe Combination?	10.1016/j.wneu.2017.07.185	—	6	58, 5	Lung cancer	metastatic	VEGF mAb	Bevacizumab	—	40	intra-cranial	brain	—	20, 1	Missing	Missing	Missing	Missing	Missing	Missing	Missing	Missing	Treatment-rel.	0	—	—	—	—	—	—
Yomo et al.	2016	Retrospective	Salvage stereotactic radiosurgery with adjuvant use of bevacizumab for heavily treated recurrent brain metastases: a preliminary report	10.1007/s11060-015-2019-3	—	5	68	Lung cancer	oligometastatic, metastatic	VEGF mAb	Bevacizumab	—	5	intra-cranial	brain	—	18 Gy @50%	15 Gy @70%	20 Gy @50%	1	1	1	18 Gy @50%	15 Gy @70%	20 Gy @50%	Treatment-rel.	—	—	2	any G3: 2 AEs	any G3: 2 pts	any G3: Anemia, GI bleeding	—
Conde-Moreno et al.	2015	Retrospective	Fractionated stereotactic radiotherapy plus bevacizumab after response to bevacizumab plus irinotecan as a rescue treatment for high-grade gliomas	10.1016/j.rpor.2015.01.004	—	9	54.8	brain	—	VEGF mAb	Bevacizumab	—	9	intra-cranial	brain	—	30	—	—	6	—	—	5	—	—	Treatment-rel.	0	0	0	—	—	—	—
Wang et al.	2014	Prospective	A new strategy of CyberKnife treatment system based radiosurgery followed by early use of adjuvant bevacizumab treatment for brain metastasis with extensive cerebral edema	10.1007/s11060-014-1488-0	Missing	8	68	Lung cancer, Colorectal cancer, Head and neck cancer, Esophagus cancer, other	metastatic	—	Bevacizumab	—	8	intra-cranial	brain	—	30	20	33	3	1	5	Missing	Missing	Missing	Treatment-rel.	—	0	—	—	—	—	—